Aim of the study: Cartilage degradation in OA is mainly due to a reduced matrix protein secretion and an increase of their degradation by matrix metalloprotease (MMP). Indeed during OA an enhanced expression and activation of MMPs is observed. The major MMPs involve in matrix protein degradation are ADAMTS-4, MMP-3 or MMP-13. However, inhibition of expression or activation of MMPs might reduce matrix degradation during OA. Furin, a proprotein convertase, is responsible for the conversion of various Pro-MMPs in active MMPs. Furin activates directly ADAMTS-4 and MMP-3, while promote indirectly the maturation of MMP-13 through other MMPs. Therefore, we hypothesised that Furin may have an impact in matrix homeostasis in joint instability. Moreover, we investigated the in vitro effect of Furin in MMP expression in murin chondrocytes.
. In both models of neuropathic pain, SD-6010 produced dose-and time-dependent inhibition of pain. In the SNL model, doses of SD-6010 from 10 mg/ kg to 100 mg/kg provided maximal efficacy at 6 hours after administration, comparable to gabapentin 30 mg/kg (Figure 2 ). Peak efficacy with both SD-6010 and gabapentin occurred between 4 and 6 hours after administration. In the CCI model, efficacy of 30 mg/kg of SD-6010 was comparable to 30 mg/kg gabapentin ( Figure 3 ). Maximal efficacy with SD-6010 treatment occurred later than with gabapentin, but SD-6010 duration of efficacy was considerably longer in CCI. In the MMT model of OA pain, SD-6010 also reduced tactile hypersensitivity at doses of 50 mg/kg and 150 mg/kg and weight bearing at all doses ( Figure 4) .
Conclusions:
The selective iNOS inhibitor SD-6010 reduces pain in rodent models of inflammatory, neuropathic, and osteoarthritis pain.
